Pirfenidone attenuates IL-1β-induced COX-2 and PGE2 production in orbital fibroblasts through suppression of NF-ƘB activity

Experimental Eye Research

Volumn 113, Issue , 2013, Pages 1-8

  Choi, Youn Hee ^a   Back, Keum Ok ^b   Kim, Hee Ja ^a   Lee, Sang Yeul ^c   Kook, Koung Hoon ^b  

^a Ewha Womans University School of Medicine   (South Korea)

^b Ajou University School of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

COX 2; IL 1 ; NF B; Orbital fibroblast; Pirfenidone; Thyroid associated ophthalmopathy

Indexed keywords

CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1BETA; IODINE; MESSENGER RNA; PIRFENIDONE; PREDNISONE; PROSTAGLANDIN E2; THIAMAZOLE;

ADULT; ARTICLE; BINDING AFFINITY; CELL CULTURE; CONTROLLED STUDY; DEGRADATION; DNA BINDING; ENDOCRINE OPHTHALMOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST; GEL MOBILITY SHIFT ASSAY; GRAVES DISEASE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MALE; ORBITAL FIBROBLAST; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84878883756     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2013.05.001     Document Type: Article

References (38)

1. Adcock I.M. Transcription Factors as Activators of Gene Transcription: AP-1 and NF-kappa B. Monaldi Archives for Chest Disease (Archivio Monaldi per le malattie del torace/Fondazione clinica del lavoro) 1997, vol. 52:178-186. IRCCS [and] Istituto di clinica tisiologica e malattie apparato respiratorio, Universita di Napoli, Secondo ateneo.
2. Aggarwal B.B. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004, 6:203-208.
3. Azuma A. Pirfenidone treatment of idiopathic pulmonary fibrosis. Therapeutic Advances in Respiratory Disease 2012, 6:107-114.
4. Azuma A., Taguchi Y., Ogura T., Ebina M., Taniguchi H., et al. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respiratory Research 2011, 12:143.
5. Bahn R.S. Graves' ophthalmopathy. The New England Journal of Medicine 2010, 362:726-738.
6. Cain W.C., Stuart R.W., Lefkowitz D.L., Starnes J.D., Margolin S., et al. Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone. International Journal of Immunopharmacology 1998, 20:685-695.
7. Cao H.J., Han R., Smith T.J. Robust induction of PGHS-2 by IL-1 in orbital fibroblasts results from low levels of IL-1 receptor antagonist expression. American Journal of Physiology. Cell Physiology 2003, 284:C1429-C1437.
8. Card J.W. Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity. Toxicological Sciences (Academic Press) 2003, 75:169-180.
9. Chen B., Tsui S., Smith T.J. IL-1 beta induces IL-6 expression in human orbital fibroblasts: identification of an anatomic-site specific phenotypic attribute relevant to thyroid-associated ophthalmopathy. Journal of Immunology 2005, 175:1310-1319.
10. Choi Y.H., Bernardi R., Pandolfi P.P., Benveniste E.N. The promyelocytic leukemia protein functions as a negative regulator of IFN-gamma signaling. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:18715-18720.
11. Garrity J.A., Bahn R.S. Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment. American Journal of Ophthalmology 2006, 142:147-153.
12. Hale M.L., Margolin S.B., Krakauer T., Roy C.J., Stiles B.G. Pirfenidone blocks the in vitro and in?vivo effects of staphylococcal enterotoxin B. Infection and Immunity 2002, 70:2989-2994.
13. Han R., Smith T.J. Induction by IL-1 beta of tissue inhibitor of metalloproteinase-1 in human orbital fibroblasts: modulation of gene promoter activity by IL-4 and IFN-gamma. Journal of Immunology 2005, 174:3072-3079.
14. Han R., Tsui S., Smith T.J. Up-regulation of prostaglandin E2 synthesis by interleukin-1beta in human orbital fibroblasts involves coordinate induction of prostaglandin-endoperoxide H synthase-2 and glutathione-dependent prostaglandin E2 synthase expression. The Journal of Biological Chemistry 2002, 277:16355-16364.
15. Kaback L.A., Smith T.J. Expression of hyaluronan synthase messenger ribonucleic acids and their induction by interleukin-1beta in human orbital fibroblasts: potential insight into the molecular pathogenesis of thyroid-associated ophthalmopathy. The Journal of Clinical Endocrinology and Metabolism 1999, 84:4079-4084.
16. Kakugawa T. Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis. European Respiratory Journal 2004, 24:57-65.
17. Kazim M., Goldberg R.A., Smith T.J. Insights into the pathogenesis of thyroid-associated orbitopathy: evolving rationale for therapy. Archives of Ophthalmology 2002, 120:380-386.
18. Kim H., Choi Y.H., Park S.J., Lee S.Y., Kim S.J., et al. Antifibrotic effect of pirfenidone on orbital fibroblasts of patients with thyroid-associated ophthalmopathy by decreasing TIMP-1 and collagen levels. Investigative Ophthalmology & Visual Science 2010, 51:3061-3066.
19. Koon H.W., Zhao D., Zhan Y., Rhee S.H., Moyer M.P., et al. Substance P stimulates cyclooxygenase-2 and prostaglandin E2 expression through JAK-STAT activation in human colonic epithelial cells. Journal of Immunology 2006, 176:5050-5059.
20. Lie P.P., Cheng C.Y., Mruk D.D. The biology of interleukin-1: emerging concepts in the regulation of the actin cytoskeleton and cell junction dynamics. Cellular and Molecular Life Sciences: CMLS 2012, 69:487-500.
21. Lin X., Yu M., Wu K., Yuan H., Zhong H. Effects of pirfenidone on proliferation, migration, and collagen contraction of human Tenon's fibroblasts in vitro. Investigative Ophthalmology & Visual Science 2009, 50:3763-3770.
22. Nakanishi H., Kaibori M., Teshima S., Yoshida H., Kwon A.H., et al. Pirfenidone inhibits the induction of iNOS stimulated by interleukin-1beta at a step of NF-kappaB DNA binding in hepatocytes. Journal of Hepatology 2004, 41:730-736.
23. O'Banion M.K. Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. Critical Reviews in Neurobiology 1999, 13:45-82.
24. Oku H. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. European Journal of Pharmacology 2008, 590:400-408.
25. Oku H., Nakazato H., Horikawa T., Tsuruta Y., Suzuki R. Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock. European Journal of Pharmacology 2002, 446:167-176.
26. Prummel M.F., Wiersinga W.M., Mourits M.P., Koornneef L., Berghout A., et al. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy. Archives of Internal Medicine 1990, 150:1098-1101.
27. Ravichandran K., Tyagi A., Deep G., Agarwal C., Agarwal R. Interleukin-1beta-induced iNOS expression in human lung carcinoma A549 cells: involvement of STAT and MAPK pathways. Indian Journal of Experimental Biology 2011, 49:840-847.
28. Schreiber E., Matthias P., Muller M.M., Schaffner W. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Research 1989, 17:6419.
29. Smith W.L., Garavito R.M., DeWitt D.L. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. The Journal of Biological Chemistry 1996, 271:33157-33160.
30. Tak P.P., Firestein G.S. NF-kappaB: a key role in inflammatory diseases. The Journal of Clinical Investigation 2001, 107:7-11.
31. Taniguchi H., Kondoh Y., Ebina M., Azuma A., Ogura T., et al. The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. Respiratory Research 2011, 12:93.
32. Teshima S., Nakanishi H., Nishizawa M., Kitagawa K., Kaibori M., et al. Up-regulation of IL-1 receptor through PI3K/Akt is essential for the induction of iNOS gene expression in hepatocytes. Journal of Hepatology 2004, 40:616-623.
33. Wakelkamp I.M., Bakker O., Baldeschi L., Wiersinga W.M., Prummel M.F. TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves' ophthalmopathy patients. Clinical Endocrinology 2003, 58:280-287.
34. Wang H.S., Cao H.J., Winn V.D., Rezanka L.J., Frobert Y., et al. Leukoregulin induction of prostaglandin-endoperoxide H synthase-2 in human orbital fibroblasts. An in vitro model for connective tissue inflammation. The Journal of Biological Chemistry 1996, 271:22718-22728.
35. Weber A., Wasiliew P., Kracht M. Interleukin-1 (IL-1) pathway. Science Signaling 2010, 3. cm1.
36. Wiersinga W.M., Prummel M.F. Pathogenesis of Graves' ophthalmopathy - current understanding. The Journal of Clinical Endocrinology and Metabolism 2001, 86:501-503.
37. Yoon J.S., Lee H.J., Choi S.H., Chang E.J., Lee S.Y., et al. Quercetin inhibits IL-1beta-induced inflammation, hyaluronan production and adipogenesis in orbital fibroblasts from Graves' orbitopathy. PloS One 2011, 6:e26261.
38. Zhong H., Sun G., Lin X., Wu K., Yu M. Evaluation of pirfenidone as a new postoperative antiscarring agent in experimental glaucoma surgery. Investigative Ophthalmology & Visual Science 2011, 52:3136-3142.